Uji Klinis Vaksin Monovalent SARS-CoV-2 mRNA Varian Omicron BA.4/5

Tahapan Penelitian : Complete
Mitra Pelaksana:
PT Etana Biotechnologies Indonesia
No Registry
Tanggal Input Registry : 26-04-2023

Primary objective Efficacy To evaluate the efficacy of ABO1020 against confirmed COVID-19 occurring from 14 days after the second dose, as compared to placebo.
Secondary objectives Efficacy 1. To evaluate the efficacy of ABO1020 against confirmed COVID-19 occuring from 14 days after the first dose in subjects. 2. To evaluate the efficacy of ABO1020 against confirmed COVID-19 after each dose. 3. To evaluate the efficacy of ABO1020 against asymptomatic SARS-CoV-2 infection after each dose. 4. To evaluate the efficacy of ABO1020 against severe confirmed COVID-19 after each dose. 5. To evaluate the efficacy of ABO1020 against different genotypes of SARS-CoV-2 virus infection after each dose Immunogenicity 1. To evaluate the humoral immunity of ABO1020 28 days after each dose, 90 days, 180 days, and 360 days after the second dose in the humoral immunity subgroup Safety 1. To evaluate the safety of ABO1020 within 28 days after each dose in all subjects. 2. To evaluate the long-term safety of ABO1020 in all subjects.
Uji Klinis Vaksin Monovalent SARS-CoV-2 mRNA Varian Omicron BA.4/5
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination
Vaksin Uji: SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) Plasebo: Physiological Saline Injection

Inclusion Criteria:

The subjects must meet all of the following inclusion criteria: 1. Voluntarily sign the ICF approved by the Ethics Committee before any study procedure and agree to participate in the study. 2. Healthy male or female able to provide legal identity certificate and aged 18 years and older when signing the ICF. 3. Subjects who have previously been fully vaccinated either by 2 or 3 doses of SARS-CoV-2 inactivated vaccine. The last dose of immunization should be >6 months before administration of the investigational products. 4. Be able to communicate well with the investigator, and to understand and comply with the requirements of this clinical trial. 5. Males and females with childbearing potential voluntarily take effective contraceptive methods from signing ICF to 3 months after completing the vaccination, including sexual abstinence or effective contraceptive measures (e.g., intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, intrauterine device [IUD], condoms [male], diaphragm, and cervical cap).

Exclusion Criteria:

Exclusion criteria for the first dose Subjects should not participate in this clinical study if any of the following criteria is met before the 1st dose of the investigational product: 1. Positive SARS-CoV-2 rapid test at screening. 2. Prior medical history of severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS). 3. Fever (axillary temperature or equivalent ≥ 37.3℃*) on the day of vaccination with this investigational vaccine or within recent 72 hours. * Tympanic Temperature °C – 0.56°C = Axillary Equivalent in °C 4. Abnormal vital signs (pulse < 60 bpm or > 100 bpm, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg when keeping awake) with clinical relevance. 5. Do not remain overall healthy (i.e., has medically deteriorated significantly since receiving the two-dose vaccination, is anticipated to have fatal outcome of uncontrolled diseases within 12 months, and is not able to provide blood as specified by the trial with anticipated, deleterious medical consequences) in the clinical judgment of the investigator based on medical history and physical examination. 6. Pregnant or lactating women, or those who plan to donate sperm or egg during the trial. 7. Prior history of allergic reaction or anaphylaxis to any vaccine or its excipients, e.g., hypersensitivity, urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc. 8. Prior use of any other vaccine within 28 days before using the investigational products or planning to use any vaccine other than the investigational products during the study period. 9. Participation in the studies of any other interventional device or drug within 30 days before the screening, or current treatment with other investigational drug(s) or within 5 half-lives after taking the last dose of the study drug. 10. Hereditary hemorrhagic tendency or coagulation dysfunction (e.g., cytokine defects, coagulation disorders or platelet disorders), or a history of serious bleeding, or a history of massive bleeding after intramuscular injection or intravenous puncture or ecchymosis. 11. Known medical history or diagnosis confirming that subjects have diseases affecting immune system function, including cancer (except skin basal cell carcinoma), congenital or acquired immunodeficiency (e.g., infection with human immunodeficiency virus [HIV]), and uncontrolled autoimmune disease. 12. Serious or uncontrolled respiratory system disorders, cardiovascular disorders, nervous system disorders, blood and lymphatic system disorders, liver and kidney disorders, metabolism and skeletal disorders, etc. influencing study results evaluation at the investigator’s discretion. 13. Asplenia or functional asplenia. 14. Long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulators (e.g., glucocorticoids: prednisone or similar drugs) within 6 months prior to administration of this investigational vaccine, except for topical medications (e.g., ointments, eye drops, inhalants or nasal sprays). And the topical medications should not exceed the recommended dose in the labels for use or induce any signs of systemic exposure. 15. Having received immunoglobulins and/or blood products within 3 months prior to administration of this investigational vaccine. 16. Suspected or known alcohol dependency or drug abuse, which may affect safety evaluation or subject’s compliance at the investigator’s discretion. 17. Planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits. 18. Receiving antituberculosis treatment. 19. Staff of study site, sponsor and contract research organization (CRO) taking part in the study. 20. Other conditions that the investigators consider unsuitable for this study.
KET-1317/UN2.F1/ETIK/PPM.00.02/2022 dan 80/KEPK-RSUPP/09/2022
Puspa Restu Sayekti